Ampligen Down, Probe Aims at Hemispherx Execs' Moves

Chronic fatigue syndrome (CFS) patients willing to take Ampligen if it's approved – and accept the risks, because it has worked for them in trials – faced off against charges of inadequately done studies with less than satisfying overall efficacy signals, during a meeting of the FDA's Arthritis Advisory Committee.